188 related articles for article (PubMed ID: 1827275)
1. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.
Vermorken JB; Gundersen S; Clavel M; Smyth JF; Dodion P; Renard J; Kaye SB
Ann Oncol; 1993 Apr; 4(4):303-6. PubMed ID: 8518220
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of iproplatin in advanced ovarian carcinoma.
Sessa C; Vermorken J; Renard J; Kaye S; Smith D; ten Bokkel Huinink W; Cavalli F; Pinedo H
J Clin Oncol; 1988 Jan; 6(1):98-105. PubMed ID: 3335895
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
[TBL] [Abstract][Full Text] [Related]
6. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
7. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
9. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma.
Twelves CJ; Ash CM; Miles DW; Thomas DG; Souhami RL
Cancer Chemother Pharmacol; 1991; 27(6):481-3. PubMed ID: 2013119
[TBL] [Abstract][Full Text] [Related]
10. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.
Friedman HS; Krischer JP; Burger P; Oakes WJ; Hockenberger B; Weiner MD; Falletta JM; Norris D; Ragab AH; Mahoney DH
J Clin Oncol; 1992 Feb; 10(2):249-56. PubMed ID: 1732426
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
[TBL] [Abstract][Full Text] [Related]
12. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
13. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
15. New platinum agents. A comparison in ovarian cancer.
Kelland LR; McKeage MJ
Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
Adams M; Kerby IJ; Rocker I; Evans A; Johansen K; Franks CR
Acta Oncol; 1989; 28(1):57-60. PubMed ID: 2650722
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.
Trask C; Silverstone A; Ash CM; Earl H; Irwin C; Bakker A; Tobias JS; Souhami RL
J Clin Oncol; 1991 Jul; 9(7):1131-7. PubMed ID: 2045855
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma.
Murphy D; Lind MJ; Prendiville J; Renninson J; Smith DR; Thompson G; Ranson M; Crowther D
Eur J Cancer; 1992; 28A(4-5):870-2. PubMed ID: 1524912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]